Adults who have been diagnosed with attention deficit hyperactivity disorder (ADHD) may be living shorter lives than they should, finds a world-first study led by UCL researchers.
Parkinson’s UK invests £2.1 million in Neumora Therapeutics for preclinical testing of new Parkinson’s drug
Parkinson’s UK is investing £2.1million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to reduce inflammation